Figure 6.
IFN-γ plays an essential role in NK-induced CD8+ responses. (A) In vivo IFN-γ blockade leads to outgrowth of Ag104Ld LIGHT tumor at the primary tumor challenge. C3B6F1 mice were subcutaneously inoculated with Ag104Ld LIGHT tumor cells and treated twice weekly with anti–IFN-γ antibody or control anti–rat Ig for 2 weeks. (B) Blocking IFN-γ causes tumor growth at the secondary tumor challenge. The C3B6F1 mice were subcutaneously inoculated with 1 × 107 Ag104Ld tumor cells after 40 days of primary Ag104Ld LIGHT tumor rejection and treated with anti–IFN-γ antibody or control anti–rat Ig as previously described. (C) IFN-γ blockade impairs NK cell–induced CD8+ cell proliferation. rLIGHT-preactivated NK cells from Rag-1-/- mice were incubated with the culture of 2C T and irradiated Ag104Ld cells with different doses of anti–IFN-γ antibody or 100 ng/mL rIFN-γ for 7 days. 3H-TdR incorporation and specific lysis assays were performed as previously described. (D) IFN-γ–deficient mice impair NK cell–induced CD8+ proliferation and lytic activity. rLIGHT-preactivated NK cells from Rag1-/- or Ifng-/- mice were added to the culture of 2C T and irradiated Ag104Ld cells at days 0, 3, and 5 for 7 days. NK cells from Ifng-/- mice showed reduced responses (P < .01). rIFN-γ was added to the culture of Ifng-/- NK cells at the indicated times. Data analysis was performed by using the Student t test. Averaged results are expressed as mean plus or minus SD.